Enjoy Free Shipping on Orders above $220
Anastroz 1 mg is an advanced hormonal therapy used in the management of hormone receptor-positive Breast Cancer in postmenopausal women. The active pharmaceutical ingredient is Anastrozole (1mg). This potent non-steroidal aromatase inhibitor selectively suppresses Estrogen biosynthesis in postmenopausal women, where Estrogen is primarily produced in peripheral tissues rather than the ovaries.
This targeted medication serves multiple therapeutic purposes in oncology, including adjuvant treatment of early-stage Breast Cancer, first-line therapy for locally advanced or metastatic Breast Cancer, and treatment of advanced Breast Cancer following Tamoxifen failure. Clinical studies have demonstrated Anastroz ability to significantly extend disease-free survival while maintaining quality of life during long-term treatment regimens.
Zuvius Life is the leading manufacturer of Anastroz 1 mg. It is renowned for its commitment to oncology therapeutics and adherence to international pharmaceutical standards, ensuring consistent potency and purity in every tablet.
Anastroz intervenes in the Estrogen production pathway through competitive inhibition of the aromatase enzyme. In postmenopausal women, this enzyme converts adrenal androgens (primarily Androstenedione and Testosterone) into Estrogen in peripheral tissues.
By binding to the aromatase enzyme, Anastroz prevents these conversions, resulting in up to 80% suppression of Estrogen synthesis, thereby depriving Estrogen-dependent tumor cells of their growth signal.
The therapeutic advantages of Anastroz extend beyond its biological mechanism:
It is crucial to note that Anastroz requires consistent daily administration to maintain therapeutic Estrogen suppression levels, and interruptions should be avoided to preserve anticancer efficacy.
Anastroz 1 mg is a prescription medication that should be taken as per your doctor's instructions. Here are the general guidelines:
Currently, there are no strength alternatives available for Anastroz. However, the following substitutes are available:
| $24.90 / 10 tablets | |
| $11.10 / 10 tablets | |
| $16.10 / 10 tablets |
Anastroz 1 mg is generally well-tolerated when compared to chemotherapy options. However, it may cause side effects, including:
These adverse effects often diminish in intensity over time as the body adapts to decreased Estrogen levels. Symptoms that significantly affect quality of life should be discussed with your healthcare provider as management strategies are available.
Liver disease
Patients with mild to moderate hepatic impairment can typically use Anastroz without dose modification, though more vigilant monitoring of liver function is recommended. In severe liver disease, the medication should be used cautiously due to potentially decreased drug clearance, which may increase plasma concentrations and the risk of adverse effects.
Kidney impairment
No dosage adjustment is generally necessary for patients with renal impairment. Anastroz is primarily metabolized in the liver with minimal renal excretion. However, patients with severe kidney dysfunction (creatinine clearance <20 mL/min) should be monitored more closely for potential drug accumulation effects.
Pregnant and breastfeeding women
Anastroz is contraindicated in pregnancy (FDA Category X) due to the risk of fetal harm, especially male fetus feminization. It's mainly for postmenopausal women with rare pregnancy concerns.
Avoid
Avoid Estrogen-containing products, including HRT and herbal supplements like red clover or soy, as they may reduce Anastroz's effect. Limit alcohol to lower osteoporosis and liver risks. Avoid grapefruit, as it may interfere with metabolism.
The standard dosage is one tablet (1 mg) taken once daily. This dosage remains consistent regardless of the indication being treated. No adjustment is typically needed for elderly patients or those with renal impairment. The full therapeutic benefit may take several weeks to manifest.
Anastroz has minimal clinically significant drug interactions. However, medications containing Estrogen will counteract its effects and should be avoided. Always inform your doctor about all your medications, including over-the-counter products and supplements, to ensure safe concurrent use.
Treatment duration ranges from 5 to 10 years, depending on your diagnosis and risk factors. Recent clinical evidence suggests extended therapy beyond 5 years may provide additional benefits in high-risk patients. Your oncologist will determine the optimal duration based on your circumstances.
Yes, Anastroz may accelerate bone mineral density loss due to Estrogen suppression. Regular bone density screening is recommended during treatment. Most physicians usually recommend calcium and vitamin D supplementation, weight-bearing exercise, and sometimes bone-protective medications like bisphosphonates to minimize this effect.
Anastroz begins suppressing Estrogen production within 24 hours of the first dose. Maximum Estrogen suppression (approximately 70-80% reduction) occurs within 3-4 days of starting treatment. However, the anticancer effects develop gradually over weeks to months as Estrogen-dependent Cancer cells are deprived of their growth stimulus.
